Matt Rosenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matt Rosenberg has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Reginald Chapple
Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
3 shared publications - Bilal Chughtai
Department of Urology, Northwell Health, Syosset, NY 11791, USA
2 shared publications D. R. Staskin
Tufts University School of Medicine, Caritas‐St. Elizabeth’s Medical Center
2 shared publications- Elizabeth Rose Mueller
Loyola University Chicago Stritch School of Medicine
2 shared publications - Fredrik L. Andersson
Ferring Pharmaceuticals, Copenhagen, Denmark
2 shared publications - Jeffrey P. Weiss
Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, USA
2 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (9) , 3765-3785
Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review
Benign prostatic hyperplasia (BPH) and overactive bladder (OAB) both cause lower urinary tract symptoms (LUTS) in men. Ongoing urgency, frequency, and nocturia despite effective BPH management may indicate coexistence of primary OAB in many individuals. A literature search was conducted to support a narrative review aimed at enhancing awareness that urinary symptoms in men should not be attributed solely to either BPH or OAB, as LUTS have numerous etiologies, and OAB and BPH are both prevalent among men. Owing to different etiologies of BPH and OAB, LUTS in men may not be adequately addressed with a single treatment. BPH medications primarily target voiding-related symptoms, and storage-related symptoms may persist. Storage-related symptoms (i.e., OAB) are generally the most bothersome and frequently reported element of LUTS, reducing quality of life, and studies suggest that OAB in men is inadequately addressed. Furthermore, men with both BPH and OAB seldom receive treatment for OAB after BPH management, if at all. Thus, men may benefit from clinicians prescribing OAB medication alongside those for BPH. This approach has been evaluated in clinical trials, some of which have shown improvements in OAB symptoms among men with BPH, without introducing additional safety concerns. Proactive discussions about symptoms, especially in the primary care setting, may help facilitate timely and effective treatment of this common issue. There are established OAB treatments that can be safely and successfully combined with BPH management to effectively address persistent storage symptoms and complex urinary symptoms in men.
- 30 June 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (9) , 3765-3785
Open AccessManagement of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review
Benign prostatic hyperplasia (BPH) and overactive bladder (OAB) both cause lower urinary tract symptoms (LUTS) in men. Ongoing urgency, frequency, and nocturia despite effective BPH management may indicate coexistence of primary OAB in many individuals. A literature search was conducted to support a narrative review aimed at enhancing awareness that urinary symptoms in men should not be attributed solely to either BPH or OAB, as LUTS have numerous etiologies, and OAB and BPH are both prevalent among men. Owing to different etiologies of BPH and OAB, LUTS in men may not be adequately addressed with a single treatment. BPH medications primarily target voiding-related symptoms, and storage-related symptoms may persist. Storage-related symptoms (i.e., OAB) are generally the most bothersome and frequently reported element of LUTS, reducing quality of life, and studies suggest that OAB in men is inadequately addressed. Furthermore, men with both BPH and OAB seldom receive treatment for OAB after BPH management, if at all. Thus, men may benefit from clinicians prescribing OAB medication alongside those for BPH. This approach has been evaluated in clinical trials, some of which have shown improvements in OAB symptoms among men with BPH, without introducing additional safety concerns. Proactive discussions about symptoms, especially in the primary care setting, may help facilitate timely and effective treatment of this common issue. There are established OAB treatments that can be safely and successfully combined with BPH management to effectively address persistent storage symptoms and complex urinary symptoms in men.
- Open Access
Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men
Prostate cancer represents a significant health risk to aging men, in which diagnostic challenges to the identification of aggressive cancers remain unmet. Prostate cancer screening is driven by the prostate-specific antigen (PSA); however, in men with benign prostatic hyperplasia (BPH) due to an enlarged prostate and elevated PSA, PSA’s screening utility is diminished, resulting in many unnecessary biopsies. To address this issue, we previously identified a cleaved fragment of Filamin A (FLNA) protein (as measured with IP-MRM mass spectrometry assessment as a prognostic biomarker for stratifying BPH from prostate cancer and subsequently evaluated its expanded utility in Caucasian (CA) and African American (AA) men. All men had a negative digital rectal examination (DRE) and PSA between 4 and 10 ng/mL and underwent prostate biopsy. In AA men, FLNA serum levels exhibited diagnostic utility for stratifying BPH from patients with aggressive prostate cancer (0.71 AUC and 12.2 OR in 48 men with BPH and 60 men with PCa) and outperformed PSA (0.50 AUC, 2.2 OR). In CA men, FLNA serum levels also exhibited diagnostic utility for stratifying BPH from patients with aggressive prostate cancer (0.74 AUC and 19.4 OR in 191 men with BPH and 109 men with PCa) and outperformed PSA (0.46 AUC, 0.32 OR). Herein, we established FLNA alone as a serum biomarker for stratifying men with BPH vs. those with high Gleason (7–10) prostate cancers compared to the current diagnostic paradigm of using PSA. This approach demonstrates clinical actionability of FLNA alone without the requirement of prostate volume measurement as a test with utility in AA and CA men and represents a significant opportunity to decrease the number of unnecessary biopsies in aggressive prostate cancer diagnoses.
Open AccessFilamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men
Prostate cancer represents a significant health risk to aging men, in which diagnostic challenges to the identification of aggressive cancers remain unmet. Prostate cancer screening is driven by the prostate-specific antigen (PSA); however, in men with benign prostatic hyperplasia (BPH) due to an enlarged prostate and elevated PSA, PSA’s screening utility is diminished, resulting in many unnecessary biopsies. To address this issue, we previously identified a cleaved fragment of Filamin A (FLNA) protein (as measured with IP-MRM mass spectrometry assessment as a prognostic biomarker for stratifying BPH from prostate cancer and subsequently evaluated its expanded utility in Caucasian (CA) and African American (AA) men. All men had a negative digital rectal examination (DRE) and PSA between 4 and 10 ng/mL and underwent prostate biopsy. In AA men, FLNA serum levels exhibited diagnostic utility for stratifying BPH from patients with aggressive prostate cancer (0.71 AUC and 12.2 OR in 48 men with BPH and 60 men with PCa) and outperformed PSA (0.50 AUC, 2.2 OR). In CA men, FLNA serum levels also exhibited diagnostic utility for stratifying BPH from patients with aggressive prostate cancer (0.74 AUC and 19.4 OR in 191 men with BPH and 109 men with PCa) and outperformed PSA (0.46 AUC, 0.32 OR). Herein, we established FLNA alone as a serum biomarker for stratifying men with BPH vs. those with high Gleason (7–10) prostate cancers compared to the current diagnostic paradigm of using PSA. This approach demonstrates clinical actionability of FLNA alone without the requirement of prostate volume measurement as a test with utility in AA and CA men and represents a significant opportunity to decrease the number of unnecessary biopsies in aggressive prostate cancer diagnoses.
- Open Access
- 1 January 2024
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 11 (1) , 18-29
A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group
To promote comprehensive care of patients throughout the androgen deprivation therapy (ADT) prescribing process, the Prostate Cancer 360 (PC360) Working Group developed monitoring and management recommendations intended to mitigate or prevent ADT-associated adverse events. The PC360 Working Group included 14 interdisciplinary experts with a dedicated clinical interest in prostate cancer and ADT management. The working group defined challenges associated with ADT adverse event management and then collaboratively developed comprehensive care recommendations intended to be practical for ADT prescribers. The PC360 Working Group developed both overarching recommendations for ADT adverse event management and specific recommendations across 5 domains (cardiometabolic, bone, sexual, psychological, and lifestyle). The working group recommends an interdisciplinary, team-based approach wherein the ADT prescriber retains an oversight role for ADT management while empowering patients and their primary and specialty care providers to manage risk factors. The PC360 recommendations also emphasize the importance of proactive patient education that involves partners or other support providers. Recommended monitoring and assessment tools, risk factor management, and patient counseling points are also included for the 5 identified domains, with an emphasis on lifestyle and behavioral interventions that can improve quality of life and reduce the risk for ADT-associated complications. Comprehensive care of patients receiving ADT requires early and ongoing coordinated management of a variety of health domains, including cardiometabolic, bone, sexual, psychological health. Patient education and primary care provider involvement should begin prior to ADT initiation and continue throughout treatment to improve patient and partner quality of life.
- 1 January 2024
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 11 (1) , 18-29
Open AccessA Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group
To promote comprehensive care of patients throughout the androgen deprivation therapy (ADT) prescribing process, the Prostate Cancer 360 (PC360) Working Group developed monitoring and management recommendations intended to mitigate or prevent ADT-associated adverse events. The PC360 Working Group included 14 interdisciplinary experts with a dedicated clinical interest in prostate cancer and ADT management. The working group defined challenges associated with ADT adverse event management and then collaboratively developed comprehensive care recommendations intended to be practical for ADT prescribers. The PC360 Working Group developed both overarching recommendations for ADT adverse event management and specific recommendations across 5 domains (cardiometabolic, bone, sexual, psychological, and lifestyle). The working group recommends an interdisciplinary, team-based approach wherein the ADT prescriber retains an oversight role for ADT management while empowering patients and their primary and specialty care providers to manage risk factors. The PC360 recommendations also emphasize the importance of proactive patient education that involves partners or other support providers. Recommended monitoring and assessment tools, risk factor management, and patient counseling points are also included for the 5 identified domains, with an emphasis on lifestyle and behavioral interventions that can improve quality of life and reduce the risk for ADT-associated complications. Comprehensive care of patients receiving ADT requires early and ongoing coordinated management of a variety of health domains, including cardiometabolic, bone, sexual, psychological health. Patient education and primary care provider involvement should begin prior to ADT initiation and continue throughout treatment to improve patient and partner quality of life.
- Open Access
- 1 July 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (1) , 144-154
Differences in the Prevalence of Nocturnal Polyuria in the U.S. by Definition: Results from the Epidemiology of Nocturnal Polyuria Study
Purpose: Prevalence data on nocturnal polyuria (NP), nocturia caused by overproduction of urine during sleep, is primarily limited to men and varies by NP definition. This U.S.-representative epidemiological study of men and women ≥30 years old assessed the prevalence of NP. Materials and Methods: Consenting participants completed the baseline EpiNP (Epidemiology of Nocturnal Polyuria) survey (eg Lower Urinary Tract Symptoms Tool, comorbidities). All reporting ≥2 voids/night and a target of 100 random respondents reporting 0 or 1 void/night were asked to complete 3-day bladder diaries. NP was defined as nocturnal polyuria index (NPI) >0.33 (NPI33) and nocturnal urine production >90 ml/hour (NUP90). Extrapolated prevalence was stratified by sex and subgroups: idiopathic (without underlying causes), associated with overactive bladder (NPOAB), bladder outflow obstruction (NPBOO; men) and comorbidities. Voided volumes and timing, including first uninterrupted sleep period, were assessed by subgroup. Results: A total of 10,190 individuals completed the baseline survey; mean age (range) was 54.4 (30–95). A total of 3,938 individuals were invited to complete the diary; 1,763 (49.3%) completed 3-day bladder diaries. Urine production (maximum nighttime volume, total volume, nocturnal urine production, nocturia index) was higher in both men and women with idiopathic NP and comorbidities. The median number of nighttime voids was greatest for NPBOO in men and NPOAB in women. Bother associated with nighttime voiding differed by NP subgroup but was highest in NPBOO for men (NPI33: 69.6%; NUP90: 71.1%) and NPOAB for women (NPI33: 67.5%; NUP90: 66.0%). Conclusions: This population-based NP prevalence study including men and women characterizes NP subgroups and provides insights into nocturia treatment by emphasizing factors influencing urine production versus factors influencing bladder capacity.
- 1 July 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (1) , 144-154
Open AccessDifferences in the Prevalence of Nocturnal Polyuria in the U.S. by Definition: Results from the Epidemiology of Nocturnal Polyuria Study
Purpose: Prevalence data on nocturnal polyuria (NP), nocturia caused by overproduction of urine during sleep, is primarily limited to men and varies by NP definition. This U.S.-representative epidemiological study of men and women ≥30 years old assessed the prevalence of NP. Materials and Methods: Consenting participants completed the baseline EpiNP (Epidemiology of Nocturnal Polyuria) survey (eg Lower Urinary Tract Symptoms Tool, comorbidities). All reporting ≥2 voids/night and a target of 100 random respondents reporting 0 or 1 void/night were asked to complete 3-day bladder diaries. NP was defined as nocturnal polyuria index (NPI) >0.33 (NPI33) and nocturnal urine production >90 ml/hour (NUP90). Extrapolated prevalence was stratified by sex and subgroups: idiopathic (without underlying causes), associated with overactive bladder (NPOAB), bladder outflow obstruction (NPBOO; men) and comorbidities. Voided volumes and timing, including first uninterrupted sleep period, were assessed by subgroup. Results: A total of 10,190 individuals completed the baseline survey; mean age (range) was 54.4 (30–95). A total of 3,938 individuals were invited to complete the diary; 1,763 (49.3%) completed 3-day bladder diaries. Urine production (maximum nighttime volume, total volume, nocturnal urine production, nocturia index) was higher in both men and women with idiopathic NP and comorbidities. The median number of nighttime voids was greatest for NPBOO in men and NPOAB in women. Bother associated with nighttime voiding differed by NP subgroup but was highest in NPBOO for men (NPI33: 69.6%; NUP90: 71.1%) and NPOAB for women (NPI33: 67.5%; NUP90: 66.0%). Conclusions: This population-based NP prevalence study including men and women characterizes NP subgroups and provides insights into nocturia treatment by emphasizing factors influencing urine production versus factors influencing bladder capacity.
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S18-S19
The prevalence of nocturnal polyuria in the US: Results from the Epidemiology of Nocturnal Polyuria (EpiNP) study
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S18-S19
The prevalence of nocturnal polyuria in the US: Results from the Epidemiology of Nocturnal Polyuria (EpiNP) study
- Open Access
- 13 July 2020
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 74 (11) , e13604
Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management
Background Overactive bladder (OAB) syndrome has a diverse etiology that disrupts quality of life domains in affected patients. OAB is significantly under‐recognized and undertreated, especially in the primary care setting. In order to educate primary care providers about OAB recognition, evaluation, and management, we created a virtual live‐streamed and enduring education program. Methods We evaluated the impact of education on provider knowledge and self‐efficacy via qualitative interviews with a sample of education participants. We analyzed participant responses via constant comparative method, an iterative approach that allows for exploration of a priori issues and identification of emergent themes. Results We identified four key themes: 1) taking OAB seriously; 2) variations in therapy; 3) patient motivation; and 4) education value. Participants were proactive about screening for and managing OAB and recognized urgency as a key symptom; some participants used diagnostic tests that are not are not considered necessary in the workup of uncomplicated OAB patients. Participants varied in their descriptions of initial approaches to treatment and most participants described a longer‐than‐recommended follow‐up window to monitor patients. Some participants characterized patients as looking for a “quick fix” in ways that could lead to provider inaction in relation to behavioral/lifestyle interventions. Overall, participants felt the education validated their current practice and provided new knowledge about evaluation, initiating behavioral treatment, and combination therapy. Conclusions Participant responses were congruent with education messages, which likely reflects their “readiness to learn”. The rationale for diagnostic tests and evidence on the effectiveness of behavioral regimens represent ongoing areas of unmet educational need.
- 13 July 2020
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 74 (11) , e13604
Open AccessTaking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management
Background Overactive bladder (OAB) syndrome has a diverse etiology that disrupts quality of life domains in affected patients. OAB is significantly under‐recognized and undertreated, especially in the primary care setting. In order to educate primary care providers about OAB recognition, evaluation, and management, we created a virtual live‐streamed and enduring education program. Methods We evaluated the impact of education on provider knowledge and self‐efficacy via qualitative interviews with a sample of education participants. We analyzed participant responses via constant comparative method, an iterative approach that allows for exploration of a priori issues and identification of emergent themes. Results We identified four key themes: 1) taking OAB seriously; 2) variations in therapy; 3) patient motivation; and 4) education value. Participants were proactive about screening for and managing OAB and recognized urgency as a key symptom; some participants used diagnostic tests that are not are not considered necessary in the workup of uncomplicated OAB patients. Participants varied in their descriptions of initial approaches to treatment and most participants described a longer‐than‐recommended follow‐up window to monitor patients. Some participants characterized patients as looking for a “quick fix” in ways that could lead to provider inaction in relation to behavioral/lifestyle interventions. Overall, participants felt the education validated their current practice and provided new knowledge about evaluation, initiating behavioral treatment, and combination therapy. Conclusions Participant responses were congruent with education messages, which likely reflects their “readiness to learn”. The rationale for diagnostic tests and evidence on the effectiveness of behavioral regimens represent ongoing areas of unmet educational need.
- 22 November 2019
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 74 (3) , e13449
Cardiovascular risk with androgen deprivation therapy
Background From the primary care perspective, many urologists and oncologists appear to be ignoring an FDA warning to assess patients' cardiovascular (CV) risk before instituting androgen deprivation therapy (ADT) with gonadotropin‐releasing hormone (GnRH) agonists. A growing body of data suggests an association between androgen deprivation therapy (ADT) and CV/cardiometabolic risk, particularly for GnRH agonists. Methodology The author examined available evidence regarding CV side effects with GnRH agonists and antagonists to determine what urologists, medical oncologists, primary care physicians (PCPs), and patients need to know about these risks. Results Data are inconclusive and somewhat conflicting — both low testosterone and testosterone replacement have been associated with elevated CV risk, for example. But the distinction between GnRH agonists and antagonists is becoming clearer, as agonists appear to be more strongly linked with CV risk, perhaps due to the transient testosterone surge they cause upon administration. Moreover, adverse CV events associated with GnRH agonists can emerge relatively quickly, within weeks to months. Conversely, two studies show that GnRH antagonists may significantly reduce CV risk compared to GnRH agonists. Conclusions Both GnRH agonists and antagonists carry some degree of CV risk. Although the risk appears to be lower with GnRH antagonists, urologists and oncologists should communicate with PCPs to determine patients' baseline CV risk levels before implementing ADT with either type of agent.
- 22 November 2019
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 74 (3) , e13449
Cardiovascular risk with androgen deprivation therapy
Background From the primary care perspective, many urologists and oncologists appear to be ignoring an FDA warning to assess patients' cardiovascular (CV) risk before instituting androgen deprivation therapy (ADT) with gonadotropin‐releasing hormone (GnRH) agonists. A growing body of data suggests an association between androgen deprivation therapy (ADT) and CV/cardiometabolic risk, particularly for GnRH agonists. Methodology The author examined available evidence regarding CV side effects with GnRH agonists and antagonists to determine what urologists, medical oncologists, primary care physicians (PCPs), and patients need to know about these risks. Results Data are inconclusive and somewhat conflicting — both low testosterone and testosterone replacement have been associated with elevated CV risk, for example. But the distinction between GnRH agonists and antagonists is becoming clearer, as agonists appear to be more strongly linked with CV risk, perhaps due to the transient testosterone surge they cause upon administration. Moreover, adverse CV events associated with GnRH agonists can emerge relatively quickly, within weeks to months. Conversely, two studies show that GnRH antagonists may significantly reduce CV risk compared to GnRH agonists. Conclusions Both GnRH agonists and antagonists carry some degree of CV risk. Although the risk appears to be lower with GnRH antagonists, urologists and oncologists should communicate with PCPs to determine patients' baseline CV risk levels before implementing ADT with either type of agent.
- 28 May 2019
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 73 (8) , e13377
It's All About the Urine, Dad
According to my son, many years ago, I was a urine doctor. In the 3rd grade, my son's teacher asked the children what their parents do in their jobs and my then 8‐year‐old proudly stated “my Dad plays with urine”. I am not exactly sure what terminology he actually used but this was how my wife lovingly related to me the day's events
- 28 May 2019
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 73 (8) , e13377
It's All About the Urine, Dad
According to my son, many years ago, I was a urine doctor. In the 3rd grade, my son's teacher asked the children what their parents do in their jobs and my then 8‐year‐old proudly stated “my Dad plays with urine”. I am not exactly sure what terminology he actually used but this was how my wife lovingly related to me the day's events
- 14 June 2017
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 71 (6) , e12953
Make the DRE great again
- 14 June 2017
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 71 (6) , e12953
Make the DRE great again
- Open Access
- 28 July 2016
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 70 (8) , 635-637
Issue Information
- 28 July 2016
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 70 (8) , 635-637
Open AccessIssue Information